$19.60 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: $19.60 Billion

As of May 2024 BeiGene has a market cap of $19.60 Billion. This makes BeiGene the world's 983th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Market cap Change
2024$19.60 B-1.07%
2023$19.81 B-15.53%
2022$23.46 B-14.65%
2021$27.48 B14.39%
2020$24.03 B133.57%
2019$10.28 B23.44%
2018$8.33 B87.28%
2017$4.45 B269.44%
2016$1.20 B

End of Day market cap according to different sources

On May 17th, 2024 the market cap of BeiGene was reported to be:

$19.60 Billion
by Yahoo Finance info icon info icon
$19.60 Billion
by CompaniesMarketCap info icon info icon
$18.07 Billion
by Nasdaq info icon info icon
$16.56 Billion
by Iex Cloud info icon info icon

Market capitalization for similar companies or competitors

Name Market cap Market cap differencediff. Country
$0.92 B-95.31%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.9 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA